Fresenius Medical Care named Korangy CEO as FMC stock trades below EUR 38.01

Published on 10/14/2026 at 13:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Korangy, 51, took over on October 12, 2026 after Helen Giza. FMC stock costs EUR 37.99 on October 14, 2026, 0.05 percent below EUR 38.01.

Leadership transition and earnings

Shervin Korangy, 51, became CEO effective October 12, 2026.
Second-quarter 2026 adjusted operating income reached EUR 569 million, up 23 percent at constant currency.
FMC stock trades at EUR 37.99 at 1:16 p.m. CEST at Lang & Schwarz on October 14, 2026, 0.05 percent below the Xetra close of October 13, 2026.
Third-quarter 2026 results are scheduled for November 3, 2026.

Moderner Dialyseraum mit Hämodialysegeräten und Patientenliegen bei Tageslicht — Ein fotorealistisches Bild eines modernen Dialyseraums mit mehreren Hämodialysegeräten und Patientenliegen in Reihe, ruhigem Tageslicht durch große Fenster – typisch für die Behandlungszentren von Fresenius Medical Care AG (ISIN DE0005785802), Illustration mit AI erstellt.

Fresenius Medical Care (ISIN DE0005785802) was trading at EUR 37.99 at Lang & Schwarz on October 14, 2026 at 1:16 p.m. CEST, 0.05 percent below the Xetra close of EUR 38.01 on October 13, 2026. The company had named Shervin J. Korangy, 51, as CEO effective October 12, 2026, according to its Fresenius Medical Care release dated October 7, 2026.

Leadership change sets the next test

Korangy succeeded Helen Giza, who had led the company as CEO and chair for four years. The appointment followed the FME25+ transformation program and puts strategic execution at the center of the next reporting cycle.

The company said Korangy would concentrate on long-term profitable growth, innovation and market leadership. For investors, the transition matters because the leadership change arrives while operating performance is improving but revenue growth remains measured.

Second-quarter margins improved

In the second quarter of 2026, revenue reached EUR 4.861 billion, up 4 percent at constant currency, while adjusted operating income rose 23 percent at constant currency to EUR 569 million. These figures were reported in a results release carried by The Globe and Mail on August 3, 2026.

The comparison is important: adjusted operating income expanded much faster than revenue, pointing to operating leverage in the quarter. The same report said Fresenius Medical Care reaffirmed its full-year 2026 outlook, while the earnings-call discussion highlighted weaker U.S. treatment volumes and reimbursement-related pressure as counter-factors.

What comes before the next report?

Fresenius Medical Care's investor calendar schedules the third-quarter 2026 results for November 3, 2026, followed by the quarterly financial report on November 6, 2026, according to the company's investor-relations page. That timetable gives the new leadership its first formal opportunity to update the market on treatment volumes, margin progression and the full-year outlook.

Analyst caution remains visible. Deutsche Bank Research kept its Hold rating and EUR 40.00 price target on October 9, 2026, citing the leadership transition and the departure of a respected manager.

Stock stays below the Xetra close

At Lang & Schwarz, FMC stock stood at EUR 37.99 in trading on October 14, 2026 at 1:16 p.m. CEST, 0.05 percent below the Xetra close of October 13, 2026 at EUR 38.01. The same-day market context included a 52-week range of EUR 33.24 to EUR 45.90 and market capitalization of EUR 10.1 billion as of October 13, 2026.

The further course of trading is shown by the continuously updated real-time quote of FMC stock.